Exit Options for John Hancock Bond and Corporate Finance Group: Hanover Communications In... - 28 Strategic Investors

View x

With a new cancer drug in the offering, Synta Pharma sees a boost in share prices

Synta Pharmaceuticals Corp., has investors lined up, awaiting the Phase III trial results of its latest cancer drug ganetespib. According to sources, Synta may also have a complementary drug to combine with ganetespib that might make it more effective. The company saw its share prices go up a 7 percent, a boost from its previous share price fall of 67 percent in 2013.


Synta Pharmaceuticals Corp,ganetespib,cancer drug